OTCMKTS:SNPHY Santen Pharmaceutical (SNPHY) Stock Price, News & Analysis → Trump Asset Seizure Threat Alert: Could Your Savings Be Next? (From American Hartford Gold Group) (Ad) Free SNPHY Stock Alerts $9.92 +0.12 (+1.23%) (As of 05/8/2024 ET) Add Compare Share Share Today's Range$9.92▼$9.9250-Day Range$9.12▼$10.4552-Week Range$8.08▼$10.80Volume389 shsAverage Volume5,102 shsMarket CapitalizationN/AP/E Ratio0.10Dividend Yield487.13%Price TargetN/A Stock AnalysisStock AnalysisChartFinancialsSEC FilingsShort InterestStock AnalysisChartFinancialsSEC FilingsShort Interest Get Santen Pharmaceutical alerts: Email Address Ad Priority GoldThe 2024 Gold Rush: Unleashing Market PotentialWelcome to the financial rollercoaster of 2024, where inflation is persistent, stock markets are overinflated and volatile, global conflicts are intensifying, and the national debt is reaching new heights.Get your free information kit NOW, before it's too late. About Santen PharmaceuticalSanten Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and marketing of pharmaceuticals and medical devices in Japan and internationally. Its product portfolio includes tafluprost/timolol maleate, a prostaglandin F2a derivative and a beta-adrenergic receptor blocker; and netarsudil mesilate and latanoprost, a prostaglandin F2a derivative which is marketing approval phase for the treatment of glaucoma and ocular hypertension. The company also offers sepetaprost, a prostaglandin analogue eye drop drug that is in phase 3 of clinical trials; and latanoprost, an ophthalmic emulsion of a prostaglandin F2a derivative which is filed for marketing approval for the treatment of glaucoma and ocular hypertension. In addition, it provides cyclosporin, an ophthalmic emulsion for the treatment of vernal keratoconjunctivitis; and diquafosol sodium for dry eye treatment. Further, the company develops olodaterol hydrochloride, a ß2 receptor agonist that is in phase 1/2a for the treatment of A dry eye treatment dry eye; sirolimus, an ophthalmic suspension which is in phase 2a for the treatment of 4 Fuchs endothelial corneal dystrophy and meibomian gland dysfunction; epinastine hydrochloride, a histamine H1 receptor antagonist filed for marketing approval for the treatment of allergic conjunctivitis; atropine sulfate, a non-selective muscarinic antagonist that is in phase 2/3 clinical trials for myopia treatment; and AFDX0250BS, an selective muscarinic M2 antagonist which is in phase 2a for the treatment of myopia. Additionally, it offers ursodeoxycholic acid that is in phase 2a of clinical trial for the treatment of presbyopia; and oxymetazoline hydrochloride, a direct-acting alpha adrenergic receptor agonist which is in phase 3 for treatment of ptosis. The company was founded in 1890 and is headquartered in Osaka, Japan.Read More SNPHY Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SNPHY Stock News HeadlinesApril 23, 2024 | morningstar.comSanten Pharmaceutical Co LtdApril 20, 2024 | wsj.comSanten Pharmaceutical Co. Ltd. ADRMay 9, 2024 | Huge Alerts (Ad)This 1 Biotech Stock has been shocking the marketsSave the Date: BioStem's 2024 Q1 Call Coming Up!December 27, 2023 | finance.yahoo.comSanten Pharmaceutical Co. Ltd. (JP3336000009.SG)October 4, 2023 | msn.comSanten Pharmaceutical Co. - ADR (SNPHY) Price Target Increased by 7.52% to 10.41August 9, 2023 | seekingalpha.comSNPHY Santen Pharmaceutical Co., Ltd.August 4, 2023 | msn.comSanten Pharmaceutical Co., Ltd. reports Q1 resultsJuly 19, 2023 | benzinga.comHarrow Acquires Santen's Branded Ophthalmic PortfolioMay 9, 2024 | Huge Alerts (Ad)This 1 Biotech Stock has been shocking the marketsSave the Date: BioStem's 2024 Q1 Call Coming Up!July 19, 2023 | businesswire.comSanten Agrees to Licensing Agreements and Asset Transfer for its Pharmaceutical Products in North AmericaMay 11, 2023 | msn.comSanten Pharmaceutical Co. reports FY resultsAugust 4, 2022 | markets.businessinsider.comSanten Pharmaceutical is about to announce its earnings — here's what to expectJuly 23, 2022 | marketwatch.comOphthalmology Equipment Market Demand Analysis & Opportunity Outlook 2029May 24, 2022 | marketwatch.comOphthalmology Equipment Market Demand, Opportunity, Outlook, Trends, Revenue, Future Growth Opportunities By2029December 2, 2021 | investing.comSanten Pharmaceutical Co (SNPHY)November 11, 2021 | seekingalpha.comSanten Pharmaceutical Co., Ltd. 2021 Q2 - Results - Earnings Call PresentationSee More Headlines Receive SNPHY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Santen Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Drug Manufacturers - General Sub-IndustryN/A Current SymbolOTCMKTS:SNPHY CUSIPN/A CIK1501108 Webwww.santen.com Phone(167) 664-8621FaxN/AEmployees4,144Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E Ratio0.10 Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMr. Takeshi Ito (Age 65)President, CEO & Representative Director Mr. Kazuo KoshijiChief Financial Officer & Chief Risk OfficerMs. Rie NakajimaCOO & Corporate OfficerMr. Minori HaraChief Digital & Information OfficerMs. Kaori ItagakiGeneral Manager of Investor Relations GroupMs. Mika MasunariGeneral Counsel & Chief Compliance OfficerMs. Nobuko KatoChief Communications OfficerMr. Satoshi Suzuki (Age 61)Senior Corporate Officer & Head of Corporate Development Division & Director Mr. Shinichi TeramachiCorporate Officer, Head of Sales Department & Japan Sales and Marketing DivisionMr. Ippei KuriharaCorporate Officer and Head of Marketing Department, Japan Business, Japan Sales & Marketing DivisionMore ExecutivesKey CompetitorsAstraZenecaOTCMKTS:AZNCFCosmo PharmaceuticalsOTC:CMOPFCSPC Pharmaceutical GroupOTCMKTS:CSPCYDaiichi SankyoOTCMKTS:DSNKYDechra PharmaceuticalsOTCMKTS:DCHPFView All Competitors SNPHY Stock Analysis - Frequently Asked Questions How have SNPHY shares performed in 2024? Santen Pharmaceutical's stock was trading at $9.85 at the start of the year. Since then, SNPHY stock has increased by 0.7% and is now trading at $9.9150. View the best growth stocks for 2024 here. Is Santen Pharmaceutical a good dividend stock? Santen Pharmaceutical (OTCMKTS:SNPHY) pays an annual dividend of $48.30 per share and currently has a dividend yield of 1.47%. The dividend payout ratio is 46.34%. This payout ratio is at a healthy, sustainable level, below 75%. How do I buy shares of Santen Pharmaceutical? Shares of SNPHY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:SNPHY) was last updated on 5/9/2024 by MarketBeat.com Staff From Our PartnersTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaThis 1 Biotech Stock has been shocking the marketsHuge AlertsDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsUrgent Nvidia WarningAltimetry348 million Americans lives to END as we know it?The Oxford ClubThe A.I. story nobody is telling you (Read ASAP)TradeSmithDems have chosen Biden replacement?Paradigm PressGlobal crypto currency reset (41 major banks signed up)Stansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Santen Pharmaceutical Co., Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.